Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC, Triplett BM, Federico S, Mamcarz E, Janssen W, Wu J, Shook D, Leung W, Furman WL. Talleur AC, et al. Among authors: mamcarz e. Biol Blood Marrow Transplant. 2017 Nov;23(11):1910-1917. doi: 10.1016/j.bbmt.2017.07.011. Epub 2017 Jul 18. Biol Blood Marrow Transplant. 2017. PMID: 28733263 Free PMC article. Clinical Trial.
Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.
Triplett BM, Muller B, Kang G, Li Y, Cross SJ, Moen J, Cunningham L, Janssen W, Mamcarz E, Shook DR, Srinivasan A, Choi J, Hayden RT, Leung W. Triplett BM, et al. Among authors: mamcarz e. Transpl Infect Dis. 2018 Feb;20(1):10.1111/tid.12823. doi: 10.1111/tid.12823. Epub 2018 Jan 16. Transpl Infect Dis. 2018. PMID: 29178554 Free PMC article. Clinical Trial.
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. Mamcarz E, et al. N Engl J Med. 2019 Apr 18;380(16):1525-1534. doi: 10.1056/NEJMoa1815408. N Engl J Med. 2019. PMID: 30995372 Free PMC article. Clinical Trial.
Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution.
Mamcarz E, Madden R, Qudeimat A, Srinivasan A, Talleur A, Sharma A, Suliman A, Maron G, Sunkara A, Kang G, Leung W, Gottschalk S, Triplett BM. Mamcarz E, et al. Bone Marrow Transplant. 2020 May;55(5):929-938. doi: 10.1038/s41409-019-0750-7. Epub 2019 Nov 18. Bone Marrow Transplant. 2020. PMID: 31740766 Free PMC article.
Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS.
Sharma A, Li Y, Huang S, Talleur AC, Suliman A, Qudeimat A, Srinivasan A, Mamcarz E, Madden R, Cheng C, Gottschalk S, Triplett BM. Sharma A, et al. Among authors: mamcarz e. Bone Marrow Transplant. 2021 Aug;56(8):1866-1875. doi: 10.1038/s41409-021-01267-0. Epub 2021 Mar 19. Bone Marrow Transplant. 2021. PMID: 33742153
Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.
Epperly R, Talleur AC, Li Y, Schell S, Tuggle M, Métais JY, Huang S, Pei D, Cheng C, Madden R, Mamcarz E, Naik S, Qudeimat A, Sharma A, Srinivasan A, Suliman A, Gottschalk S, Triplett BM. Epperly R, et al. Among authors: mamcarz e. Transplant Cell Ther. 2022 May;28(5):262.e1-262.e10. doi: 10.1016/j.jtct.2022.02.007. Epub 2022 Feb 11. Transplant Cell Ther. 2022. PMID: 35151936 Free PMC article. Clinical Trial.
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.
Talleur AC, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng EA, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou SM, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S. Talleur AC, et al. Among authors: mamcarz e. Blood Adv. 2022 Nov 8;6(21):5737-5749. doi: 10.1182/bloodadvances.2021006293. Blood Adv. 2022. PMID: 35446934 Free PMC article. Clinical Trial.
Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Pfeiffer T, Li Y, Ashcraft E, Karol SE, Rubnitz JE, Epperly R, Madden R, Mamcarz E, Obeng E, Qudeimat A, Sharma A, Srinivasan A, Suliman A, Talleur AC, Velasquez MP, Gottschalk S, Triplett BM, Naik S. Pfeiffer T, et al. Among authors: mamcarz e. Bone Marrow Transplant. 2023 Mar;58(3):328-331. doi: 10.1038/s41409-022-01877-2. Epub 2022 Nov 29. Bone Marrow Transplant. 2023. PMID: 36443431 No abstract available.
20 results